The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer
Frontiers in Oncology · 16.01.2023 · 12
DOI: 10.3389/fonc.2022.1060864 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 16.01.2023. Verfasst von Caitlin R Davies und 20 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK.
Abstract (Originalsprache)
Background
Docetaxel improves overall survival (OS) in castration-resistant prostate cancer (PCa) (CRPC) and metastatic hormone-sensitive PCa (mHSPC). However, not all patients respond due to inherent and/or acquired resistance. There remains an unmet clinical need for a robust predictive test to stratify patients for treatment. Liquid biopsy of circulating tumour cell (CTCs) is minimally invasive, can provide real-time information of the heterogeneous tumour and therefore may be a potentially ideal docetaxel response prediction biomarker.
Objective
In this study we investigate the potential of using CTCs and their gene expression to predict post-docetaxel tumour response, OS and progression free survival (PFS).
Methods
Peripheral blood was sampled from 18 mCRPC and 43 mHSPC patients, pre-docetaxel treatment, for CTC investigation. CTCs were isolated using the epitope independent Parsortix ® system and gene expression was determined by multiplex RT-qPCR. We evaluated CTC measurements for post-docetaxel outcome prediction using receiver operating characteristics and Kaplan Meier analysis.
Results
Detection of CTCs pre-docetaxel was associated with poor patient outcome post-docetaxel treatment. Combining total-CTC number with PSA and ALP predicted lack of partial response (PR) with an AUC of 0.90, p= 0.037 in mCRPC. A significantly shorter median OS was seen in mCRPC patients with positive CTC-score (12.80 vs. 37.33 months, HR= 5.08, p= 0.0005), ≥3 total-CTCs/7.5mL (12.80 vs. 37.33 months, HR= 3.84, p= 0.0053), ≥1 epithelial-CTCs/7.5mL (14.30 vs. 37.33 months, HR= 3.89, p= 0.0041) or epithelial to mesenchymal transitioning (EMTing)-CTCs/7.5mL (11.32 vs. 32.37 months, HR= 6.73, p= 0.0001). Significantly shorter PFS was observed in patients with ≥2 epithelial-CTCs/7.5mL (7.52 vs. 18.83 months, HR= 3.93, p= 0.0058). mHSPC patients with ≥5 CTCs/7.5mL had significantly shorter median OS (24.57 vs undefined months, HR= 4.14, p= 0.0097). In mHSPC patients, expression of KLK2 , KLK4 , ADAMTS1 , ZEB1 and SNAI1 was significantly associated with shorter OS and/or PFS. Importantly, combining CTC measurements with clinical biomarkers increased sensitivity and specificity for prediction of patient outcome.
Conclusion
While it is clear that CTC numbers and gene expression were prognostic for PCa post-docetaxel treatment, and CTC subtype analysis may have additional value, their potential predictive value for docetaxel chemotherapy response needs to be further investigated in large patient cohorts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
- Department of Cell Biology and the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Central Biobank, Medical University of Gdansk, Gdansk, Poland.
- Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
- Department of Urology, Barts Health National Health Service Trust (NHS), London, United Kingdom.
Förderung
- Cancer Research UK
Zitieren
APA
Davies, C. R., Guo, T., Burke, E., Stankiewicz, E., Xu, L., Mao, X., Scandura, G., Rajan, P., Tipples, K., Alifrangis, C., Wimalasingham, A. G., Galazi, M., Crusz, S., Powles, T., Grey, A., Oliver, T., Kudahetti, S., Shaw, G., Berney, D., …, & Lu, Y. J. (2023). The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1060864
Vancouver
Davies CR, Guo T, Burke E, Stankiewicz E, Xu L, Mao X, et al. The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer. Frontiers in Oncology. 2023;12. doi:10.3389/fonc.2022.1060864
BibTeX
@article{Davies2023,
author = {Davies, Caitlin R and Guo, Tianyu and Burke, Edwina and Stankiewicz, Elzbieta and Xu, Lei and Mao, Xueying and Scandura, Glenda and Rajan, Prabhakar and Tipples, Karen and Alifrangis, Constantine and Wimalasingham, Akhila Ganeshi and Galazi, Myria and Crusz, Shanthini and Powles, Thomas and Grey, Alistair and Oliver, Tim and Kudahetti, Sakunthala and Shaw, Greg and Berney, Daniel and Shamash, Jonathan and Lu, Yong-Jie},
title = {The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer},
journal = {Frontiers in Oncology},
year = {2023},
volume = {12},
doi = {10.3389/fonc.2022.1060864}
}
EUVIMED